Sara Corr, MD
Internal Medicine · Denver, CONPI 1942435680
Payments from drug & device makers
Across 115 payments — averaging $14.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$176
- AbbVie$162
- Novo Nordisk$137
- Lilly USA, LLC$137
- GSK$127
- Johnson & Johnson$125
- plus $785 from 23 others
What the payments were for
- Food & beverage$1,61398%
- Education$352%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 12 | $176 |
| AbbVie(2 entities) | 9 | $162 |
| Novo Nordisk | 9 | $137 |
| Lilly USA, LLC | 14 | $137 |
| GSK | 8 | $127 |
| Johnson & Johnson | 9 | $125 |
| Amgen(2 entities) | 8 | $120 |
| E.r. Squibb & Sons, L.L.C. | 7 | $96 |
| Boehringer Ingelheim | 6 | $93 |
| Astellas Pharma US Inc | 5 | $77 |
| Novartis | 4 | $66 |
| Pfizer | 3 | $39 |
| Amarin Pharma, Inc. | 3 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Hikma Pharmaceuticals USA | 2 | $23 |
| Genentech USA, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $18 |
| Nalpropion Pharmaceuticals LLC | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Therapeuticsmd, Inc. | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $13 |
| Aytu Biopharma, Inc. | 1 | $13 |
| Merck | 1 | $13 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| IBSA Pharma Inc. | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $12 |
How this compares
$1,648 in reported general payments places this provider in the 85th percentile of 1,430 internal medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 98 | $122,806 |
| XareltoRivaroxaban | 42 | $64,667 |
| TrulicityDulaglutide | 39 | $62,913 |
| MounjaroTirzepatide | 54 | $58,937 |
| OzempicSemaglutide | 37 | $55,172 |
| JardianceEmpagliflozin | 21 | $34,590 |
| MyrbetriqMirabegron | 28 | $31,521 |
| BelsomraSuvorexant | 19 | $11,424 |
| SynthroidLevothyroxine Sodium | 105 | $7,693 |
| Atorvastatin Calcium | 472 | $4,487 |
| Rosuvastatin Calcium | 302 | $3,889 |
| Estradiol | 44 | $3,598 |
| Levothyroxine Sodium | 294 | $3,504 |
| Omeprazole | 173 | $3,179 |
| Gabapentin | 104 | $2,533 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $39 | $122,80698 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $137 | $121,85093 claims |
| Johnson & JohnsonXarelto | $125 | $64,66742 claims |
| Novo NordiskOzempic | $137 | $55,17237 claims |
| Boehringer IngelheimJardiance | $93 | $34,59021 claims |
| Astellas Pharma US IncMyrbetriq | $77 | $31,52128 claims |
| MerckBelsomra | $13 | $11,42419 claims |
| AbbVieSynthroid | $162 | $7,693105 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,430 internal medicine providers in Colorado.
Other internal medicine in Denver
- Jason HenryDenver$7.3M
- Thomas StarkeyDenver$391K
- Matthew KoslowDenver$182K
- Keith HruskaDenver$167K
- Kenneth OleszekDenver$60K
- Robert KeithDenver$49K
- Elena AnisimovaDenver$36K
- Chase BlackfordDenver$30K
- Samuel BrownDenver$18K
- Katherine TsaiDenver$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.